Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Zoe Lombardi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Biomedical Sciences, University of Florence, Italy. Hauptthemen laut MEDLINE: beta Karyopherins, Cell Proliferation, Mitogen-Activated Protein Kinase 7, Cell Nucleus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero dell'Istruzione, dell'Università e della Ricerca, European Union Horizon 2020 Research and Innovation Program.
Abstract (Originalsprache)
The mitogen‐activated protein kinase (MAPK) extracellular signal‐regulated kinase 5 (ERK5) is emerging as a promising target in cancer. Indeed, alterations of the MEK5/ERK5 pathway are present in many types of cancer, including melanoma. One of the key events in MAPK signalling is MAPK nuclear translocation and its subsequent regulation of gene expression. Likewise, the effects of ERK5 in supporting cancer cell proliferation have been linked to its nuclear localization. Despite many processes regulating ERK5 nuclear translocation having been determined, the nuclear transporters involved have not yet been identified. Here, we investigated the role of importin subunit alpha (α importin) and importin subunit beta‐1 (importin β1) in ERK5 nuclear shuttling to identify additional targets for cancer treatment. Either importin β1 knockdown or the α/β1 importin inhibitor ivermectin reduced the nuclear amount of overexpressed and endogenous ERK5 in HEK293T and A375 melanoma cells, respectively. These results were confirmed in single‐molecule microscopy in HeLa cells. Moreover, immunofluorescence analysis showed that ivermectin impairs epidermal growth factor (EGF)‐induced ERK5 nuclear shuttling in HeLa cells. Both co‐immunoprecipitation experiments and proximity ligation assay provided evidence that ERK5 and importin β1 interact and that this interaction is further induced by EGF administration and prevented by ivermectin treatment. The combination of ivermectin and the ERK5 inhibitor AX15836 synergistically reduced cell viability and colony formation ability in A375 and HeLa cells and was more effective than single treatments in preventing the growth of A375 and HeLa spheroids. The increased reduction of cell viability upon the same combination was also observed in patient‐derived metastatic melanoma cells. The combination of ivermectin and ERK5 inhibitors other than AX15836 provided similar effects on cell viability. The identification of importin β1 as the nuclear transporter of ERK5 may be exploited for additional ERK5‐inhibiting strategies for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Biomedical Sciences, University of Florence, Italy.
- National Institute of Optics, National Research Council, Florence, Italy.
- European Laboratory of Non-Linear Spectroscopy (LENS), Florence, Italy.
- Department of Physics and Astronomy, University of Florence, Italy.
- Core Research Laboratory - Institute for Cancer Research and Prevention (ISPRO), Florence, Italy.
ORCID-Profile: Elisabetta Rovida
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Ministero dell'Istruzione, dell'Università e della Ricerca
- European Union Horizon 2020 Research and Innovation Program
- Fondazione Cassa di Risparmio di Firenze
- European Union
- Fondazione AIRC per la ricerca sul cancro ETS
- European Commission
Zitieren
APA
Lombardi, Z., Gardini, L., Kashchuk, A. V., Menconi, A., Lulli, M., Tusa, I., Tubita, A., Maresca, L., Stecca, B., Capitanio, M., & Rovida, E. (2025). Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Molecular Oncology. https://doi.org/10.1002/1878-0261.13674
Vancouver
Lombardi Z, Gardini L, Kashchuk AV, Menconi A, Lulli M, Tusa I, et al. Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Molecular Oncology. 2025. doi:10.1002/1878-0261.13674
BibTeX
@article{Lombardi2025,
author = {Lombardi, Zoe and Gardini, Lucia and Kashchuk, Anatolii V and Menconi, Alessio and Lulli, Matteo and Tusa, Ignazia and Tubita, Alessandro and Maresca, Luisa and Stecca, Barbara and Capitanio, Marco and Rovida, Elisabetta},
title = {Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13674}
}
EUVIMED